James H. Revkin

James H. Revkin

Cardiology

70 Francis Street
Carl J. And Ruth Shapiro Cardiovascular Center
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.

Journal: The Lancet. Haematology

Published: November 15, 2025

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review.

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review.

Journal: Heliyon

Published: December 22, 2023

The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.

The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.

Journal: Journal of cachexia, sarcopenia and muscle

Published: December 01, 2023

Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.

Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.

Journal: Journal of cachexia, sarcopenia and muscle

Published: September 05, 2023

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.

Journal: Journal of cachexia, sarcopenia and muscle

Published: August 31, 2023

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 07, 2023

ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor.

ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor.

Journal: American heart journal

Published: October 27, 2021

Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week.

Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week.

Journal: Journal of the American College of Cardiology

Published: February 24, 2021

Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank.

Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank.

Journal: American heart journal

Published: February 18, 2020

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

Journal: Journal of clinical lipidology

Published: January 02, 2018

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Journal: The New England journal of medicine

Published: March 18, 2017

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Journal: The New England journal of medicine

Published: March 18, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026